Don't miss this virtual event on the 30th April!

Learn about the challenges and considerations of biomarker testing for #lungcancer and #ProstateCancer with experts Fernando López-Ríos, Alicia Morgans, MD, MPH & Herbert Loong

Register here 👉ow.ly/2sqR50R25wA

#MedEd

Expert Laurence Albiges brings us a review of the renal cell carcinoma (RCC) emerging data likely to impact clinical practice

Did you miss any important updates from the #ESMO23 symposium? Find out with Laurence Albiges

ow.ly/y53z50QRcXT

#MedEd #RCC

Recognise inherited risk and inform treatment decision-making

This #MedEd program delves into applying genetic testing to mCRPC treatment using PARP inhibitors with anti-androgens

> CME credit
> ZERO Prostate Cancer endorsed
> With Alicia Morgans, MD, MPH & pas_rescigno
ow.ly/NAkV50QRbFX

Genetic testing aids treatment decision-making and understanding inherited risk

Module 1 of this e-learning program delves into PARP inhibitors as monotherapy in mCRPC

> CME credits
> ZERO Prostate Cancer endorsed
> With Alicia Morgans, MD, MPH & pas_rescigno
#MedEd
ow.ly/pga850QR4rF

📣US oncology nurses - don't miss your chance to have your say!

How is your role as an oncology #nurse evolving?

Your opinion counts!

Spare 10-15 mins & take the survey before it closes.

👉 ow.ly/kyMq50QyRWB

Answers are anonymous.

#NurseTwitter #OncologyNursing #MedEd

Intermediate/poor-risk patients with advanced ccRCC receive combined immunotherapy with VEGFR TKI

But how can we optimise treatment while managing adverse events for these patients?

Find out in our interactive programme led by Viktor Grünwald: ow.ly/LR7Z50QRcLc
#MedEd

PARPIs with NHAs are effective as first-line treatment in mCRPC patients with HRR mutations

Discover more in this micro learning program with Alicia Morgans and Pasquale Rescigno

> CME credit
> ZERO Prostate Cancer endorsed
> With Alicia Morgans, MD, MPH & pas_rescigno
ow.ly/WRbB50QRbM5

Intermediate/poor-risk pts with advanced ccRCC receive combined immunotherapy with VEGFR TKI

But how can we optimise treatment while managing adverse events for these patients?

Find out in our interactive programme led by Viktor Grünwald

tinyurl.com/y9pc6yhe

#MedEd

Engaging #MedEd to help you manage adverse events for patients with advanced ccRCC receiving combined immunotherapy-VEGFR TKI

Improve your decision making with our interactive programme 'Optimising treatment for advanced RCC' led by Viktor Grünwald

ow.ly/6Hcn50QRe2C

PARP inhibitors are effective as monotherapy in mCRPC patients with HRR alterations, as discussed in this micro-e-learning program with Alicia Morgans and Pasquale Rescigno

> CME credits
> ZERO Prostate Cancer endorsed
> With Alicia Morgans, MD, MPH & pas_rescigno
#MedEd
ow.ly/AmiN50QR4hQ

Expert Laurence Albiges brings us a review of the renal cell carcinoma (RCC) emerging data likely to impact clinical practice

Need a recap of the important updates from the #ESMO23 symposium? Listen with expert Laurence Albiges here

ow.ly/G4MA50QRcQf

#MedEd #RCC

Learn about the use of PARP inhibitors combined with anti-androgens in prostate cancer with Alicia Morgans and Pasquale Rescigno in Module 2 of this micro e-learning course

> CME credits
> ZERO Prostate Cancer endorsed
> With Alicia Morgans, MD, MPH & pas_rescigno
#MedEd
ow.ly/8W8N50QRbJT

Intermediate/poor-risk patients with advanced ccRCC receive combined immunotherapy with VEGFR TKI

But how can we optimise treatment while managing adverse events for these patients?

Find out in our interactive programme led by Viktor Grünwald: ow.ly/jKLp50QRcJQ
#MedEd

Better understand the use of PARP inhibitors as monotherapy in prostate cancer with Alicia Morgans and Pasquale Rescigno in Module 1. of this micro e-learning course

> CME credits
> ZERO Prostate Cancer endorsed
> With Alicia Morgans, MD, MPH & pas_rescigno
#MedEd
ow.ly/qpaS50QR3by

As promised, we have updated our micro-e-learning program with the latest data.

👉ow.ly/6mpc50QwtCE

In Module 1, Alicia Morgans and Pasquale Rescigno cover the use of PARP inhibitors as monotherapy in advanced prostate cancer.

>Get CME credits
>ZERO Prostate Cancer @EAUN endorsed

🔔Paper in Annals of Oncology in mCRPC patients shows that BRCA mutations (somatic and germline) result in worse outcomes than non-BRCA HRR mutations, and HRR non-BRCA mutations result in worse outcomes than non-HRR mutations

David Olmos Elena Castro #MedEd
ow.ly/mMzM50QMuI9

This Phase 3 trial, published in Annals of Oncology, suggests that in patients with untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib gives better PFS (18.0 vs 9.8 months) and ORR than sunitinib and had a manageable safety profile

ow.ly/Wu1n50QJaTN

Join Dr. Neal Shore as he guides you through application of PARP inhibitors as monotherapy in mCRPC

🌟 Discover the influence of genetic testing on PARP inhibitor treatment

The video is animated for ease of learning
Endorsed by ZERO Prostate Cancer & NASPCC ow.ly/LPaR50QInFl

Unlock the potential of combined immunotherapy and VEGFR TKI for advanced ccRCC patients!

Join our interactive patient case video with expert Viktor Grünwald to learn how to optimize treatment and handle adverse events effectively

👉ow.ly/jpQi50QG4Wq
#MedEd

Calling all healthcare professionals! Do you or your colleagues work with lung cancer patients?

If so, you can help us bridge the gap in patient knowledge about #lungcancer biomarker testing

Share our survey and contribute to providing better support

ow.ly/whKB50QFB7y